The eHealth Diabetes Remission Trial - Pilot Study (eDIT-pilot)
Ten study participants will consume a low-calorie total diet replacement for 12 weeks, have a 6-week food reintroduction phase (week 13-18) and continue with the weight loss maintenance phase until the end of the study (week 19-26). The weight loss goal is 15 kg (or 15% if body weight is bellow 80 kg). The primary study outcome iw weight loss after 6 months and the co-primary outcome is diabetes remission after 6 months (HbA1c < 48 mmol/mol). During the weight maintenance phase, if weight regain occurs or if HbA1c increases a rescue plan of total diet replacement will be recommended.
The participants will be supplied with the total diet replacement Modifast free of charge. Participants will be supplied with a scale, a finger-stick blood glucose meter and a blood pressure monitor. Participants will be advised to measure body weight, blood glucose and blood pressure every morning. The results are registered in the mobile phone application Telia Health Monitoring and are wirelessly transmitted to the project's physician, nurse and dietician. At the beginning of the food reintroduction phase the participants will receive an activity tracer and will be advised to increase their physical activity. Primary and secondary outcome measures will be estimated at the beginning and after 3 and 6 months. At the end of the study, all participants will take part in an individual semi-structured interview to investigate the participants' experience of diabetes remission and of the eHealth contact with the healthcare provider. After participants have completed the study, they will be followed at least once per year by obtaining data on blood sugar, HbA1c, body weight, blood pressure, medication usage and diabetes complications from the healthcare computer system.
Studie Overzicht
Toestand
Conditie
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
-
Umeå, Zweden, 90187
- Department of Public Health and Clinical Medicine, Medicine
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Type 2 diabetes with diabetes duration 0 to 6 years
- BMI 27-45 kg/m2
- Owning a smartphone
- HbA1c 43-107 mmol/mol during the past 12 months (48-107 mmol/mol without blood sugar lowering medication)
Exclusion Criteria:
- Insulin treatment
- Weight loss 5 kg or more during the past 6 months
- Treatment with weight loss medication
- Diagnosed eating disorder
- eGFR < 30 ml/min/1.73m2
- Substance abuse
- Cancer
- Myocardial infarction during the past 6 months
- Severe heart failure
- Pregnancy
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Diabetes remission using total diet replacement and eHealth contact with the healthcare provider
This study has only one arm and no comparator.
|
Participants will replace usual foods with the commercially available total diet replacement Modifast (Impolin AB), which is delivered to them during the study period without any cost.
Participants will be supplied with a scale, a finger-stick blood glucose meter and a blood pressure monitor and will be advised to measure body weight, fasting blood glucose and blood pressure every morning.
The results are registered in the mobile phone application Telia Health Monitoring (Telia Sweden AB) and are wirelessly transmitted to the study team.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Weight loss
Tijdsspanne: 6 months
|
Weight loss goal of 15 kg, measured at the research facilities
|
6 months
|
|
HbA1c
Tijdsspanne: 6 months
|
The goal is diabetes remission with HbA1c < 48 mmol/mol without any diabetes medication.
(Secondary goal < 42 mmol/mol.)
|
6 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Semi-structured interviews
Tijdsspanne: 6 months
|
6 months
|
|
|
Fasting blood glucose
Tijdsspanne: Daily measurements up to 6 months
|
Partial diabetes remission (< 7.0 mol/l), complete diabetes remission (<6.1 mol/l)
|
Daily measurements up to 6 months
|
|
Fasting blood glucose
Tijdsspanne: 6 months
|
Partial diabetes remission (<7.0 mol/l), complete diabetes remission (<6.1 mol/l) without diabetes medication.
|
6 months
|
|
P-glucose 120 minutes after the oral glucose tolerance test
Tijdsspanne: 6 months
|
Measured at the research facilities
|
6 months
|
|
Insulin secretion
Tijdsspanne: At baseline, 3 months and 6 months
|
Measured with oral glucose tolerance test
|
At baseline, 3 months and 6 months
|
|
Insulin sensitivity
Tijdsspanne: At baseline, 3 months and 6 months
|
Measured with oral glucose tolerance test
|
At baseline, 3 months and 6 months
|
|
Metabolic flexibility
Tijdsspanne: At baseline, 3 months and 6 months
|
Measured with indirect calorimetry during oral glucose tolerance test
|
At baseline, 3 months and 6 months
|
|
Blood pressure (systolic/diastolic)
Tijdsspanne: At baseline, 3 months and 6 months
|
Measured at the research facilities
|
At baseline, 3 months and 6 months
|
|
Blood pressure (systolic/diastolic)
Tijdsspanne: Daily measurements up to 6 months
|
Measured at home
|
Daily measurements up to 6 months
|
|
Blood pressure medication
Tijdsspanne: 6 months
|
Change of blood pressure medication during the study
|
6 months
|
|
Body weight
Tijdsspanne: Daily measurements up to 6 months
|
Measured at home
|
Daily measurements up to 6 months
|
|
HbA1c
Tijdsspanne: Monthly measurement up to 6 months
|
Measured at home
|
Monthly measurement up to 6 months
|
|
Diabetes medication
Tijdsspanne: 6 months
|
Change of diabetes medication during study duration
|
6 months
|
|
Plasma lipid profile
Tijdsspanne: At baseline, 3 months and 6 months
|
Measured at the research facilities
|
At baseline, 3 months and 6 months
|
|
Waist circumference
Tijdsspanne: Baseline, 3 months and 6 months
|
Measured in cm at the research facilities
|
Baseline, 3 months and 6 months
|
|
EQ-5D-5L
Tijdsspanne: At baseline, 3 months and 6 months
|
Questionnaire
|
At baseline, 3 months and 6 months
|
|
Food frequency form
Tijdsspanne: At baseline and 6 months
|
Questionnaire
|
At baseline and 6 months
|
|
Daily steps
Tijdsspanne: During the second three months of the study
|
Measured with activity tracker
|
During the second three months of the study
|
|
HbA1c follow up
Tijdsspanne: Yearly up to 20 years
|
Collected from patient journals after study completion
|
Yearly up to 20 years
|
|
Body weight follow up
Tijdsspanne: Yearly up to 20 years
|
Collected from patient journals after study completion
|
Yearly up to 20 years
|
|
Blood pressure follow up (systolic/diastolic)
Tijdsspanne: Yearly up to 20 years
|
Collected from patient journals after study completion
|
Yearly up to 20 years
|
|
Antidiabetic medication usage follow up
Tijdsspanne: Yearly up to 20 years
|
Collected from patient journals after study completion
|
Yearly up to 20 years
|
|
Blood pressure medication usage follow up
Tijdsspanne: Yearly up to 20 years
|
Collected from patient journals after study completion
|
Yearly up to 20 years
|
|
Diabetes complications follow up
Tijdsspanne: Yearly up to 20 years
|
Collected from patient journals and registries after study completion
|
Yearly up to 20 years
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Julia Otten, MD, PhD, Umeå University
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- Dnr 2021-00318
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .